Eupraxia Pharmaceuticals Raises $63M to Expand GI Drug Trials
Event summary
- Eupraxia Pharmaceuticals reported a net loss of $12.7M in Q1 2026, up from $6.8M in Q1 2025 due to increased R&D costs.
- The company completed a $63.2M public offering in February 2026, issuing 7.6M common shares at $7.00 each.
- Eupraxia reported positive 36-week data from its RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE).
- The company has $140M in cash, sufficient to fund operations into H2 2028.
The big picture
Eupraxia Pharmaceuticals is leveraging its Diffusphere™ technology to develop targeted drug delivery solutions for gastrointestinal diseases. The recent $63.2M fundraising and positive clinical data for EP-104GI position the company to expand its pipeline and accelerate development in new indications. The biotech sector is increasingly focused on precision drug delivery, and Eupraxia's approach could differentiate it in a competitive market.
What we're watching
- Clinical Trial Progress
- The pace at which Eupraxia can advance EP-104GI through Phase 2b and into additional indications will determine its market potential.
- Financial Runway
- Whether the $140M in cash reserves will be sufficient to cover increased R&D costs and operational expenses until H2 2028.
- Regulatory Headwinds
- The impact of potential tariffs on the cost of active pharmaceutical ingredients and clinical supplies.
Related topics